ROCKVILLE, Md. – In a resounding celebration of scientific innovation, the American Society of Human Genetics (ASHG) has officially announced the recipients of its prestigious 2026 Publication Awards. This annual honor, bestowed by the editorial boards of the society’s premier journals—The American Journal of Human Genetics (AJHG) and Human Genetics and Genomics Advances (HGG Advances)—recognizes the vital contributions of trainees and early-career investigators who are pushing the boundaries of what is known about the human genome.
The announcement serves as a precursor to the ASHG 2026 Annual Meeting, where these rising stars will be formally honored during a special ceremony in Montréal on October 22. As the field of genetics transitions from the era of mapping to the era of complex functional interpretation, these researchers represent the vanguard of discovery, providing the computational and clinical tools necessary to decode the intricacies of human health and disease.
The Vanguard of Discovery: 2026 Award Recipients
The 2026 awards highlight a diverse array of methodological approaches, ranging from advanced machine learning applications in polygenic prediction to the fundamental characterization of rare pathogenic variants.
AJHG Award for Outstanding Trainee Publication
This award is specifically designed to celebrate the intellectual rigor of ASHG members currently completing their doctoral or postdoctoral training. It recognizes work that not only demonstrates technical mastery but also offers novel insights that shift the scientific paradigm.
- Nikolas Baya, PhD (Center for Genomic Medicine, Massachusetts General Hospital / Broad Institute of MIT and Harvard): Baya is recognized for his groundbreaking work, "Individuals who deviate from polygenic expectation are enriched for damaging variants in genes linked to rare disease." His research provides a bridge between common, complex trait genetics and the high-impact, rare variant studies that have historically been siloed.
- Kathryn A. Lawrence, BS (Stanford University): Lawrence’s research, "Focus on single-gene effects limits discovery and interpretation of complex-trait-associated variants," challenges the traditional "one gene, one disease" narrative, urging the field to adopt more holistic approaches when interpreting the vast, interconnected landscape of the human genome.
HGG Advances Early Career Investigator Award
This category highlights individuals who have recently transitioned into independent research careers. It acknowledges those who are establishing their own laboratories and setting the agenda for the next generation of genomic inquiry.
- Quan Sun, PhD (Children’s Hospital of Philadelphia / University of Pennsylvania): Dr. Sun’s paper, "Variational autoencoder-based model improves polygenic prediction in blood cell traits," showcases the application of deep learning to improve the accuracy and utility of polygenic risk scores—a critical step toward the integration of genomics into personalized clinical medicine.
- Cindy A. Thomas-Charles, PhD (University of Hartford): Dr. Thomas-Charles is recognized for her work, "Investigating and correcting a rare pathogenic mutation in GDF11." Her study represents the gold standard of translational genetics: identifying a specific molecular defect and exploring the mechanisms to potentially correct it.
A Chronology of Genomic Excellence
The selection process for these awards is a rigorous year-long endeavor. It begins with the submission of thousands of papers to the AJHG and HGG Advances editorial offices. Throughout 2026, the editorial boards track high-impact publications, looking for articles that demonstrate statistical robustness, novel biological insights, and clear potential for clinical application.
By mid-summer, the editors-in-chief and advisory boards compile a shortlist of candidates based on citation metrics, peer-review scores, and feedback from the broader scientific community. Following a final review by the ASHG Awards Committee, the winners are selected and notified in September. This year’s announcement, made on September 24, 2026, marks the final stage of this selection cycle, setting the stage for the formal recognition at the October Annual Meeting.
Supporting Data: Why These Papers Matter
The 2026 award-winning papers address the "bottlenecks" currently preventing the widespread clinical implementation of genomic medicine.
1. Moving Beyond Monogenic Bias
Kathryn Lawrence’s work is particularly timely. For decades, the field was dominated by the study of single-gene disorders (monogenic). However, most common health conditions—such as heart disease, diabetes, and mental health disorders—are polygenic, meaning they are influenced by thousands of variants across the genome. Lawrence’s analysis provides the empirical evidence that our current over-reliance on single-gene models acts as a "blinder," preventing us from identifying the true genetic architecture of complex, widespread diseases.
2. The Power of Predictive Modeling
Dr. Quan Sun’s research addresses the issue of "missing heritability." While we can map common variants, we often struggle to predict an individual’s actual risk. By utilizing variational autoencoders—a sophisticated form of generative AI—Sun has developed a model that better captures the non-linear relationships between genetic variants. This is a crucial step in ensuring that polygenic risk scores are not just statistically significant, but clinically actionable.
3. Rare Disease and Pathogenic Impact
Dr. Nikolas Baya’s work serves as a necessary check on polygenic risk scores. He discovered that individuals who appear as "outliers" in polygenic models are not merely statistical noise; they are often carriers of rare, highly damaging mutations. This finding has massive implications for clinical screening, suggesting that extreme polygenic scores could act as a "triage" signal to look for rare, high-impact genetic mutations that require immediate clinical intervention.
Official Responses and Perspectives
The leadership at ASHG emphasizes that these awards are not just about individual achievement, but about the health of the entire scientific ecosystem.
"The work showcased by this year’s winners exemplifies the trajectory of our field," said an ASHG spokesperson. "These investigators are not just analyzing data; they are developing the frameworks that will allow us to move from the ‘what’ of the genome to the ‘how’ of human health. Their ability to synthesize high-level computational data with profound biological questions is exactly what the future of genetics requires."
The recipients themselves have expressed gratitude for the mentorship and institutional support they received at their respective universities and hospitals. Dr. Cindy A. Thomas-Charles noted in a statement that "the ability to investigate rare mutations is only possible through the collaborative environment fostered by societies like ASHG."
Implications for the Future of Medicine
The implications of these award-winning studies reach far beyond the pages of academic journals.
- Precision Diagnostics: By refining how we interpret polygenic risk, researchers like Dr. Sun are making it possible for doctors to provide more personalized preventative care, potentially identifying risks for blood-related disorders years before clinical symptoms manifest.
- Targeted Therapies: Dr. Thomas-Charles’s work on GDF11 highlights the potential for gene-correction therapies. As we become better at identifying the precise, rare variants that drive disease, the pathway to gene-editing interventions becomes clearer.
- Policy and Ethics: As genomic data becomes more central to healthcare, the work of these young investigators underscores the need for robust ethical frameworks. Understanding the limitations of our models—as Lawrence points out—is essential to ensuring that genomic medicine is equitable and accurate for diverse populations.
Conclusion: Join the Conversation in Montréal
As the 2026 Annual Meeting in Montréal approaches, the excitement within the genetics community is palpable. The meeting serves as a global hub for the exchange of ideas, where these four award winners will join thousands of other experts to discuss the next frontier: the integration of functional genomics into routine clinical practice.
For journalists, policymakers, and the public, the 2026 ASHG Publication Awards offer a glimpse into the future. They remind us that the human genome is a vast, complex language, and thanks to the diligence, creativity, and technical prowess of investigators like Baya, Lawrence, Sun, and Thomas-Charles, we are becoming more fluent in that language every day.
Press registration for the 2026 Annual Meeting remains open, providing an opportunity for members of the media to engage directly with these award-winning researchers and witness the future of genomic medicine firsthand.
About the American Society of Human Genetics (ASHG)
Founded in 1948, the American Society of Human Genetics (ASHG) is the primary professional membership organization for human genetics specialists worldwide. With a membership of nearly 8,000 professionals—including researchers, clinicians, genetic counselors, and educators—the Society is dedicated to promoting the science of human genetics and its application to the improvement of human health. ASHG facilitates this mission through its annual meetings, the publication of the AJHG and HGG Advances, and by serving as a leading voice in public policy and advocacy for the genomic sciences. For more information, visit www.ashg.org.
About the Author
